Dyslipidemia
Dyslipidemia is a metabolic disorder characterized by abnormal levels of lipids or lipoproteins in the blood, often due to poor diet, lifestyle factors, and genetic causes, and is a significant risk factor for atherosclerotic cardiovascular diseases. It typically involves elevated blood lipids, such as cholesterol and triglycerides, and requires a comprehensive cardiovascular risk assessment that considers comorbid conditions and overall lifestyle.
Health Outcomes
- Altered Fatty Acid Profile in Offspring
- Altered Lipid Metabolism
- Atherogenic Lipid Profile
- Decreased HDL Cholesterol Level
- Distinct Metabolic Profile
- Elevated Insulin Levels
- Elevated Triglyceride Levels
- Enhanced Lipid Metabolism in Adipose Tissue
- Enhanced Metabolic Processing of Dietary Molecules
- Improved ApoB-100/ApoA-1 Ratio
- Improved Atherosclerosis-Related Cardiovascular Risk Markers
- Improved Bioactivity
- Improved Blood Biochemical Parameter
- Improved Blood Biochemistry
- Improved Blood Clinical Chemistry
- Improved Blood Lipid Profile
- Improved Cardiometabolic Health
- Improved Cardiovascular Disease Marker
- Improved Cholesterol Levels
- Improved Cholesterol Metabolism
- Improved FGF21 Sensitivity
- Improved Fatty Acid Profile
- Improved Flow-Mediated Vasodilation
- Improved General Health Perception
- Improved High-Density Lipoprotein Level
- Improved High-Intensity Intermittent Exercise Performance
- Improved LDL-C to HDL-C Ratio
- Improved Lipid Metabolism
- Improved Lipid Serum Homeostasis
- Improved Low-Density Lipoprotein Composition
- Improved Metabolic Disease Markers
- Improved Metabolic Disorders
- Improved Metabolic Homeostasis
- Improved Metabolic Profile
- Improved Metabolic Syndrome Remission
- Improved Obesity Metrics
- Improved Obesity Parameters
- Improved Plasma Cholesterol Clearance
- Improved Plasma Lipid Levels
- Improved Post-Myocardial Infarction Outcome
- Improved Retinal Vascular Health
- Improved Serum Averages
- Improved Serum Lipids
- Improved Serum Parameters
- Improved Stress-Strain Index
- Improved Systemic Health
- Improved Systemic Metabolism
- Improved VLDL Cholesterol
- Improved Weight Management
- Increased Adiponectin Levels
- Increased Alpha-Tocopherol Level
- Increased Apolipoprotein A-1 Level
- Increased Bioactivity
- Increased Body Mass Index
- Increased Body Weight
- Increased Branched Chain Amino Acid Levels
- Increased Free Fatty Acid Levels
- Increased High-Density Lipoprotein Level
- Increased LDL Cholesterol Level
- Increased LDL Particle Size
- Increased Lipid Oxidation
- Increased Plasma ApoA-V Levels
- Increased Total Cholesterol Level
- Increased Triglyceride Level
- Maintained Total Cholesterol Level
- Maintained Triglyceride Level
- Modified Serum Metabolomic Pathways
- Multiple Health-Promoting Effects
- No Change in Body Weight or Cardiometabolic Parameters
- No Change in Metabolic Health
- No Significant Change in Total Cholesterol
- Normalized Lipid Metabolism
- Normalized Serum Lipid Levels
- Prevention of Hypercholesterolemia
- Reduced Adipocyte Senescence
- Reduced Aortic Thickness
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Atherogenic Coefficient
- Reduced Atherogenic Effect
- Reduced Atherogenic Index
- Reduced Atherosclerosis Risk Factors
- Reduced Blood Stream Cholesterol
- Reduced Campesterol Absorption
- Reduced Cardiovascular Disease
- Reduced Cardiovascular Disease Risk
- Reduced Cardiovascular Mortality
- Reduced Cardiovascular Risk Profile
- Reduced Castelli Risk Index I
- Reduced Castelli's Risk Index II
- Reduced Cerebrovascular Mortality
- Reduced Cholesterol Synthesis
- Reduced Coronary Heart Disease Risk
- Reduced Epididymal Fat Tissue Accumulation
- Reduced Fasting Insulin Level
- Reduced Flavonoid Levels
- Reduced HDL Cholesterol Level
- Reduced HMG-CoA Reductase Inhibition
- Reduced High-Density Lipoprotein Cholesterol Level
- Reduced Hypercholesterolemia
- Reduced Hyperlipidemia Symptoms
- Reduced Insulin Sensitivity
- Reduced LDL Cholesterol Level
- Reduced LDL Level
- Reduced Lipid Concentrations
- Reduced Lipid Level
- Reduced Lipid Synthesis Enzyme Levels
- Reduced Lipoprotein Combine Index
- Reduced Low-Density Lipoprotein Level
- Reduced Lysophosphatidylethanolamine 18:1 Level
- Reduced Metabolic Disease Risk
- Reduced Metabolic Disorders Incidence
- Reduced Metabolic Dysregulation
- Reduced Metabolic Syndrome
- Reduced Non-Communicable Disease Risk
- Reduced Plasma Non-Cholesterol Sterols
- Reduced Plasma Triglycerides
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Glycemic Response
- Reduced Postprandial Triacylglycerol Response
- Reduced Risk of Coronary Heart Disease
- Reduced SCD1 Activity
- Reduced Serum Lipid Levels
- Reduced Steatosis Score
- Reduced Sugar-Sweetened Beverage Intake
- Reduced Symptoms of High-Fat Diet Pathologies
- Reduced Triglyceride Level
- Reduced Triglyceride Levels
- Reduced VLDL Cholesterol Level
- Reduced Very Low-Density Lipoprotein Level
- Reduced Very-Low-Density Lipoprotein Cholesterol
- Reduced Yolk Cholesterol Content
- Regulated Lipid Metabolism
- Remission of Metabolic Syndrome
- Restored Lipid Metabolism
- Stable HDL Cholesterol Levels
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Plasma Cholesterol Levels
- Unchanged HDL Cholesterol Level
- Unchanged LDL Cholesterol Level